We next divided 50 lung cancer patients into the CCR8-high and low groups based on the median value of the percentage of CCR8+ Tregs in CD45+ cells and found that the disease-free survival (DFS) of the CCR8-high group was significantly shorter than that of the CCR8-low group (p = 0.011) (Fig. 2B). This evidence concerns the gene CCR8 and lung carcinoma.